piracetam has been researched along with Dizziness in 13 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind crossover study we evaluated the antitremor effect of a 4-week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor." | 9.15 | Levetiracetam in primary orthostatic tremor: a double-blind placebo-controlled crossover study. ( Deuschl, G; Hellriegel, H; Raethjen, J; Volkmann, J, 2011) |
| "To evaluate the efficacy and safety of 3,000 mg daily levetiracetam (LEV; Keppra) as an adjunctive therapy for Chinese patients with refractory partial seizures." | 9.14 | Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. ( Li, JM; Lv, Y; Sun, HB; Wang, XF; Xi, ZQ; Xiao, F; Xiao, Z, 2009) |
| "The objectives of this pilot trial were to assess the potential efficacy and safety of levetiracetam for the treatment of hot flashes, a major cause of morbidity among breast cancer survivors." | 9.13 | Levetiracetam for the treatment of hot flashes: a phase II study. ( Bardia, A; Barton, DL; Christensen, B; Kottschade, L; Loprinzi, CL; Sloan, JA; Smith, D; Tan, A; Thompson, S, 2008) |
| "To prospectively assess the safety and efficacy of levetiracetam in patients with uncontrolled focal epilepsy, in a common practice-based setting." | 9.12 | Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. ( Despland, PA; Fejerman, N; Genton, P; Maubrey, MC; Peltola, J; Rektor, I; Sadzot, B; Schlit, AF; Steinhoff, B; van Hammée, G; van Paesschen, W; Vandervelden, C; Wroe, S, 2006) |
| "This subanalysis compared the efficacy of betahistine plus piracetam dual therapy versus betahistine monotherapy using data from OSVaLD, a 3 month, open-label, observational study conducted in 2272 patients with peripheral vestibular vertigo." | 7.81 | Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD study. ( Lilenko, SV; Melnikov, OA; Nauta, J; Ouwens, MJ, 2015) |
| "A pilot study with piracetam (Nootropil; UCB) was performed in 5 selected dizzy patients who had a diagnosis of presbyvertigo or vertebrobasilar insufficiency." | 7.67 | The use of piracetam in vertigo. ( Fernandes, CM; Samuel, J, 1985) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 6.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "In a double-blind crossover study we evaluated the antitremor effect of a 4-week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor." | 5.15 | Levetiracetam in primary orthostatic tremor: a double-blind placebo-controlled crossover study. ( Deuschl, G; Hellriegel, H; Raethjen, J; Volkmann, J, 2011) |
| "To evaluate the efficacy and safety of 3,000 mg daily levetiracetam (LEV; Keppra) as an adjunctive therapy for Chinese patients with refractory partial seizures." | 5.14 | Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. ( Li, JM; Lv, Y; Sun, HB; Wang, XF; Xi, ZQ; Xiao, F; Xiao, Z, 2009) |
| "The objectives of this pilot trial were to assess the potential efficacy and safety of levetiracetam for the treatment of hot flashes, a major cause of morbidity among breast cancer survivors." | 5.13 | Levetiracetam for the treatment of hot flashes: a phase II study. ( Bardia, A; Barton, DL; Christensen, B; Kottschade, L; Loprinzi, CL; Sloan, JA; Smith, D; Tan, A; Thompson, S, 2008) |
| "To prospectively assess the safety and efficacy of levetiracetam in patients with uncontrolled focal epilepsy, in a common practice-based setting." | 5.12 | Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. ( Despland, PA; Fejerman, N; Genton, P; Maubrey, MC; Peltola, J; Rektor, I; Sadzot, B; Schlit, AF; Steinhoff, B; van Hammée, G; van Paesschen, W; Vandervelden, C; Wroe, S, 2006) |
| "This subanalysis compared the efficacy of betahistine plus piracetam dual therapy versus betahistine monotherapy using data from OSVaLD, a 3 month, open-label, observational study conducted in 2272 patients with peripheral vestibular vertigo." | 3.81 | Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD study. ( Lilenko, SV; Melnikov, OA; Nauta, J; Ouwens, MJ, 2015) |
| " We could not demonstrate any association between the paradoxical effect of levetiracetam and type of epilepsy or the antiepileptic comedication used." | 3.74 | The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. ( Barcs, G; Clemens, Z; Fabó, D; Holló, A; Jakus, R; Janszky, J; Kelemen, A; Rásonyi, G; Szucs, A, 2008) |
| "A pilot study with piracetam (Nootropil; UCB) was performed in 5 selected dizzy patients who had a diagnosis of presbyvertigo or vertebrobasilar insufficiency." | 3.67 | The use of piracetam in vertigo. ( Fernandes, CM; Samuel, J, 1985) |
| " Adverse events were reported in 34 (72." | 2.72 | Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. ( Chen, SS; Edrich, P; Hiersemenzel, R; Hsih, MS; Lai, CW; Tsai, JJ; Yen, DJ, 2006) |
| " Adverse events reported after IV administration of LEV ( | 2.72 | Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ( Daoust, A; Lu, ZS; Otoul, C; Ramael, S; Stockis, A; Toublanc, N; Troenaru, M, 2006) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 2.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "The migraine--a benign paroxysmal vertigo of childhood complex is the most frequent etiology of pediatric dizziness, with an incidence of 34." | 1.30 | The migraine: benign paroxysmal vertigo of childhood complex. ( Arroyo, R; Calvin, FJ; de Lucas, P; Herraiz, C; Tapia, MC, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Melnikov, OA | 1 |
| Lilenko, SV | 1 |
| Nauta, J | 1 |
| Ouwens, MJ | 1 |
| Xiao, Z | 1 |
| Li, JM | 1 |
| Wang, XF | 1 |
| Xiao, F | 1 |
| Xi, ZQ | 1 |
| Lv, Y | 1 |
| Sun, HB | 1 |
| Zakharov, VV | 1 |
| Hellriegel, H | 1 |
| Raethjen, J | 1 |
| Deuschl, G | 1 |
| Volkmann, J | 1 |
| Briggs, DE | 1 |
| French, JA | 1 |
| Tsai, JJ | 1 |
| Yen, DJ | 1 |
| Hsih, MS | 1 |
| Chen, SS | 1 |
| Hiersemenzel, R | 1 |
| Edrich, P | 1 |
| Lai, CW | 1 |
| Genton, P | 1 |
| Sadzot, B | 1 |
| Fejerman, N | 1 |
| Peltola, J | 1 |
| Despland, PA | 1 |
| Steinhoff, B | 1 |
| Rektor, I | 1 |
| Wroe, S | 1 |
| Maubrey, MC | 1 |
| Vandervelden, C | 1 |
| van Hammée, G | 1 |
| Schlit, AF | 1 |
| van Paesschen, W | 1 |
| Ramael, S | 1 |
| Daoust, A | 1 |
| Otoul, C | 1 |
| Toublanc, N | 1 |
| Troenaru, M | 1 |
| Lu, ZS | 1 |
| Stockis, A | 1 |
| Thompson, S | 1 |
| Bardia, A | 1 |
| Tan, A | 1 |
| Barton, DL | 1 |
| Kottschade, L | 1 |
| Sloan, JA | 1 |
| Christensen, B | 1 |
| Smith, D | 1 |
| Loprinzi, CL | 1 |
| Mazza, M | 1 |
| Martini, A | 1 |
| Scoppetta, M | 1 |
| Mazza, S | 1 |
| Szucs, A | 1 |
| Clemens, Z | 1 |
| Jakus, R | 1 |
| Rásonyi, G | 1 |
| Fabó, D | 1 |
| Holló, A | 1 |
| Barcs, G | 1 |
| Kelemen, A | 1 |
| Janszky, J | 1 |
| Herraiz, C | 1 |
| Calvin, FJ | 1 |
| Tapia, MC | 1 |
| de Lucas, P | 1 |
| Arroyo, R | 1 |
| Fernandes, CM | 1 |
| Samuel, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial Studying the Safety and Efficacy of Keppra® as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy[NCT00630968] | Phase 4 | 1,541 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus[NCT00603135] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn | ||
| A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury[NCT04836481] | 20 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for piracetam and Dizziness
| Article | Year |
|---|---|
Levetiracetam safety profiles and tolerability in epilepsy patients.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Animals; Anticonvulsants; Astheni | 2004 |
7 trials available for piracetam and Dizziness
| Article | Year |
|---|---|
Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticonvulsants; Body Weight; Chemotherapy, Adjuvant; | 2009 |
Levetiracetam in primary orthostatic tremor: a double-blind placebo-controlled crossover study.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Cross-Over Studies; Dizziness; Double-Blind Method; Female | 2011 |
Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Anticonvulsants; Asian People; Cross-Over Studies; Dizziness; Double-Blind Method | 2006 |
Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.
Topics: Adult; Anticonvulsants; Disorders of Excessive Somnolence; Dizziness; Dose-Response Relationship, Dr | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam for the treatment of hot flashes: a phase II study.
Topics: Breast Neoplasms; Dizziness; Fatigue; Female; Hot Flashes; Humans; Levetiracetam; Middle Aged; Nootr | 2008 |
Effect of levetiracetam on depression and anxiety in adult epileptic patients.
Topics: Adult; Age Factors; Anticonvulsants; Anxiety Disorders; Depressive Disorder; Dizziness; Epilepsies, | 2008 |
5 other studies available for piracetam and Dizziness
| Article | Year |
|---|---|
Betahistine plus piracetam dual therapy versus betahistine monotherapy for peripheral vestibular vertigo: a confounder-corrected subanalysis of the OSVaLD study.
Topics: Adult; Aged; Betahistine; Dizziness; Female; Humans; Male; Middle Aged; Odds Ratio; Piracetam; Vasod | 2015 |
[Vinpotropil in the treatment of dyscirculatory encephalopathy with cognitive impairment without dementia].
Topics: Adult; Aged; Cognition Disorders; Dementia, Vascular; Dizziness; Drug Administration Schedule; Drug | 2010 |
The risk of paradoxical levetiracetam effect is increased in mentally retarded patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Disorders of Excessive Somnolence; Dizziness; Drug | 2008 |
The migraine: benign paroxysmal vertigo of childhood complex.
Topics: Adolescent; Child; Child, Preschool; Diazepam; Dizziness; Female; Humans; Infant; Male; Migraine Dis | 1999 |
The use of piracetam in vertigo.
Topics: Aged; Dizziness; Electronystagmography; Female; Humans; Male; Middle Aged; Pilot Projects; Piracetam | 1985 |